| Name | Title | Contact Details |
|---|
Somos una empresa internacional especializada en startups y empresas tech de LATAM. Acompañamos el crecimiento acelerado de los founders garantizándoles en cada etapa el cumplimiento de todos sus compromisos financieros, contables, impositivos y legales en cada país en el que operan. Nuestras soluciones contemplan servicios de compliance, impuestos internacionales, softlanding, CFO Services, transaction services y legal services. Nos caracterizamos por nuestra velocidad de respuesta, profesionalismo y calidad en la ejecución.
Based in the Pacific Northwest of the United States, SSC North America is a hypercar manufacturer that specializes in limited production vehicles for elite clientele around the world. In 2007, the SSC Ultimate Aero, a high performance hypercar produced by SSC, legitimized the companys standing as a leading player in the worldwide hypercar market by officially becoming the "Worlds Fastest Production Car" as witnessed and recorded by Guinness World Records. The Ultimate Aero achieved an average two-way speed of 256.18 mph, making SSC one of only 26 manufactures in world history to hold this prestigious title. Today, SSC North America is in the late development stages of the next world record breaking hypercar, the Tuatara. With the Ultimate Aeros record setting achievements and the world renowned performance brought by the next generation Tuatara, SSC North America stands firmly as a great American hypercar company, and will continue to lead innovation in the hypercar market.
Bridge Specialty Group, LLC was launched in February 2021 by Brown & Brown, Inc. to encompass its broad portfolio of wholesale insurance businesses and is focused on bringing the power of its collective size and specialty to the wholesale brokerage marketplace. Composed of more than 25 boutique brands, Bridge Specialty Group is creating a more seamless way to connect the varying needs of our retail partners with the market clout and talents of our wholesale entities. To learn more about Bridge Specialty Group and our team of niche-focused brands, visit our website at bridgespecialtygroup.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.